Ocugen Appoints New Finance Chief to Steer Gene Therapy Pipeline Toward Approval

Ocugen US67577C1053

Biotechnology firm Ocugen has announced the appointment of Rita Johnson-Greene as its new Chief Financial Officer, effective February. The leadership change comes as the company prepares for a critical multi-year period, targeting the submission of its first Biologics License Application (BLA) later this year for its gene therapy pipeline.

The company framed the appointment as a strategic move to bolster its organizational strength ahead of pivotal regulatory filings. Ocugen aims to submit three BLAs over the coming years, with the initial submission targeted for 2024. Chief Executive Officer Dr. Shankar Musunuri described the coming period as "transformative" for the company.

Johnson-Greene brings over two decades of healthcare industry experience to the role. She most recently served as Chief Operating Officer at the Alliance for Regenerative Medicine (ARM), where her responsibilities encompassed operations, finance, and international expansion.

Commercialization Expertise Takes Center Stage

A significant aspect of the new CFO's background is her hands-on experience with commercial launches in the gene therapy sector. Prior to her role at ARM, she was Vice President of Sales and Qualified Treatment Centers at Genetix Biotherapeutics (formerly bluebird bio). In that position, she led the establishment and scaling of U.S. commercial infrastructure for the launches of gene therapies ZYNTEGLO and SKYSONA.

Her career also includes senior roles at Spark Therapeutics, where she contributed to the launch of LUXTURNA—one of the first FDA-approved gene therapies in the United States for an inherited retinal disease. Earlier professional experience includes finance, commercial operations, and sales positions at AstraZeneca across North and South America, as well as strategic consulting at Accenture.

Financial Runway and Clinical Progress

Ocugen's financial position was recently strengthened by a capital raise completed in January. The company generated gross proceeds of $22.5 million through a public offering, with net proceeds amounting to $20.85 million after deducting associated costs. Management stated this capital extends its liquidity runway through the fourth quarter of 2026.

Alongside the financing update, the company highlighted positive preliminary Phase 2 data for its OCU410 program, which is being developed for geographic atrophy secondary to dry age-related macular degeneration (AMD).

Key Data Points:
* The new CFO, Rita Johnson-Greene, assumes her position in February.
* Ocugen targets its first BLA submission in 2024.
* Net proceeds of $20.85 million from a January offering are expected to fund operations into Q4 2026.
* Preliminary Phase 2 data for OCU410 in geographic atrophy (dry AMD) have been reported as positive.

The immediate focus for Ocugen remains the preparation of its first BLA submission this year, an effort now supported by both secured financing and enhanced leadership with specific commercialization experience.